Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.

Investlytic score: 1/5 criteria met.
- ❌ Price trend failed
- ❌ Growth failed
- ✅ Debt passed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: -37.25%
Price change 2019 → 2020: 14.34%
Price change 2020 → 2021: 29.62%
Price change 2021 → 2022: -70.16%
Price change 2022 → 2023: -8.11%
Price change 2023 → 2024: 40.20%
Price change 2024 → 2025: -20.98%
Price change 2025 → 2026: 11.50%
Price change 2026 (year to date): 4.13%
Financial growth
Revenue CAGR (8 years): N/A
Earnings CAGR (8 years): N/A
Growth status: insufficient data or negative trend.
Debt
Debt-to-equity ratio: 0.00
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -2.98
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 32.26% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="NNVC" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| NanoViricides, Inc. | – | 0.00 | – | 🔒 |
| Novacyt S.A. | – | 0.45 | +28.1 % | – |
| genOway S.A. | 19.8 | 0.55 | +7.2 % | – |
| Diagnostic Medical Systems S.A. | – | 0.98 | +7.0 % | – |
| Valbiotis S.A. | – | 0.73 | +56.9 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Accounts and financial health
Balance sheet and cash flow published by NanoViricides, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Cash and investments | 14.1 m | 8.1 m | 4.8 m | 1.6 m | 2.8 m |
| Total Debt | 94,788 | 0 | 0 | 0 | 0 |
| Net Debt | -14.0 m | -8.1 m | -4.8 m | -1.6 m | -2.8 m |
| Equity | 23.1 m | 14.9 m | 11.5 m | 7.5 m | 8.7 m |
| Total assets | 23.5 m | 16.9 m | 12.8 m | 8.8 m | 9.9 m |
| Operating cash flow | -5.9 m | -5.7 m | -6.3 m | -8.5 m | -7.7 m |
| Investments (capex) | 324,348 | 151,712 | 156,560 | 56,964 | 84,317 |
| Free cash-flow | -6.2 m | -5.8 m | -6.5 m | -8.5 m | -7.8 m |
| Share buybacks | 0 | 0 | 0 | 0 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
Amounts in USD, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 16/11/2026.
Dividends and earnings
NanoViricides, Inc.: dividend history, last distributions, stock splits and earnings releases.
No known dividend for this company.
Earnings releases
| Date | Published EPS | Expected EPS | Surprise |
|---|---|---|---|
| 28/09/2026 | -0.10 | -0.10 | n/a |
| 02/09/2026 | -0.11 | -0.10 | n/a |
| 21/05/2026 | -0.10 | -0.13 | n/a |
| 17/02/2026 | -0.11 | -0.14 | n/a |
| 14/11/2025 | -0.10 | -0.18 | n/a |
| 29/09/2025 | -0.13 | -0.20 | n/a |
Stock splits
| Date | Operation |
|---|---|
| 24/09/2019 | reverse split: 1 share for 20 |
| 10/09/2013 | reverse split: 2 share for 7 |
Factual data: ex-dividend history and earnings calendar, as of 17/11/2026. A past dividend does not guarantee the next one.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about NanoViricides, Inc.
What is the NanoViricides, Inc. share price?
Latest recorded price: 1.23 USD on 13/11/2026, for a market cap of 31.4 m USD.
Is NanoViricides, Inc. stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN US6300873022).
How many employees does NanoViricides, Inc. have?
7 full-time employees according to the latest published profile.
Who runs NanoViricides, Inc.?
Anil R. Diwan is the company's chief executive.